CBD News Aggregator – The United Kingdom Home Office has changed the classification of GW Pharmaceuticals‘ Epidyolex — a treatment for epileptic conditions including Dravet syndrome — from a Schedule 2 drug to a Schedule 5 drug. This move will make the medication easier to obtain.

“The decision to move Epidyolex to a low level of control is an important one for patients, their families, healthcare professionals, pharmacists and the NHS [National Health Service] as a whole — reducing costs and ensuring the medicine can be dispensed more easily,” Chris Tovey, chief operating officer of GW, said in a press release.

Epidyolex (known as Epidiolex in the U.S.) is an oral solution of cannabidiol (CBD). CBD is derived from the cannabis plant, but it is not psychoactive — that is, it doesn’t induce the “high” commonly associated with cannabis use.